Hu Shuwen, Xu Zidi, Yan Jie, Liu Min, Sun Bing, Li Wenjing, Sang Yanmei
National Key Discipline of Pediatrics, Capital Medical University, Ministry of Education, Endocrine and Genetic Metabolic Center, Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
J Pediatr Endocrinol Metab. 2012;25(11-12):1119-22. doi: 10.1515/jpem-2012-0224.
To study the treatment effect and safety of diazoxide on patients with congenital hyperinsulinism (CHI).
A total of 44 patients who have been hospitalized to our hospital and used diazoxide as a trial after diagnosis of CHI were chosen as research subjects. The clinical data of the patients were analyzed, and the treatment effects and safety of diazoxide on CHI were evaluated.
In the 44 patients studied, the blood glucoses of 36 cases recovered to normal level after using diazoxide, indicating that the 36 patients respond to the treatment of diazoxide. Eight cases still showed severe hypoglycemia after using diazoxide for 10 days, which indicated that the eight patients were unresponsive to diazoxide treatment. Eighteen patients suffered the side effect of fluid retention, and 12 patients suffered transient gastrointestinal reactions.
Diazoxide is a first-line treatment of CHI with high safety. Most of the patients with CHI were responsive to diazoxide treatment. Diazoxide should be used as a trial immediately after CHI diagnosis was made.
研究二氮嗪对先天性高胰岛素血症（CHI）患者的治疗效果及安全性。
选取我院收治的44例诊断为CHI后使用二氮嗪进行试验的患者作为研究对象。分析患者的临床资料，评估二氮嗪对CHI的治疗效果及安全性。
在研究的44例患者中，36例患者使用二氮嗪后血糖恢复至正常水平，表明这36例患者对二氮嗪治疗有反应。8例患者使用二氮嗪10天后仍表现为严重低血糖，表明这8例患者对二氮嗪治疗无反应。18例患者出现液体潴留的副作用，12例患者出现短暂的胃肠道反应。
二氮嗪是CHI的一线治疗药物，安全性高。大多数CHI患者对二氮嗪治疗有反应。CHI诊断明确后应立即使用二氮嗪进行试验。
